Literature DB >> 2658303

Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.

P A Reay1, I M Jones, F M Gotch, A J McMichael, G G Brownlee.   

Abstract

We have investigated the recognition of the PB1, neuraminidase, and matrix (M1) proteins of influenza virus A/NT/60/68 (H3N2 subtype) by secondary in vitro stimulated polyclonal cytotoxic T lymphocyte (CTL) populations. While these three proteins have different functions and cellular locations, they can all be recognized as target antigens. However, the immunogenicity of these proteins for CTLs is under strict genetic control. Thus, PB1 protein is recognized as a cross-reactive target antigen by CTLs raised in CBA (H-2k) but not BALB/c (H-2d) mice. CBA, but not BALB/c mice, also generate a low-level CTL response to the neuraminidase. This latter response was only detectable following in vivo priming of CBA mice with a recombinant vaccinia virus expressing neuraminidase (N2-VACC). The matrix protein, expressed from recombinant vaccinia virus M-VACC, was not recognized as an antigen by CTL generated from either CBA or BALB/c strains of mice. By contrast, human HLA-A2-restricted influenza virus-specific CTLs were shown to recognize this matrix protein as a target antigen. Endogenous expression of as little as 90 amino acids of the matrix protein was sufficient to render target cells susceptible to lysis by such CTLs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658303     DOI: 10.1016/0042-6822(89)90439-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

2.  Immunogenic peptides of influenza virus subtype N1 neuraminidase identify a T-cell determinant used in class II major histocompatibility complex-restricted responses to infectious virus.

Authors:  C J Hackett; D Horowitz; M Wysocka; L C Eisenlohr
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Cellular immune correlates of protection against symptomatic pandemic influenza.

Authors:  Saranya Sridhar; Shaima Begom; Alison Bermingham; Katja Hoschler; Walt Adamson; William Carman; Thomas Bean; Wendy Barclay; Jonathan J Deeks; Ajit Lalvani
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

4.  Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets.

Authors:  S H Seo; R G Webster
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Immunization with baculovirus-expressed recombinant rotavirus proteins VP1, VP4, VP6, and VP7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice.

Authors:  T Dharakul; M Labbe; J Cohen; A R Bellamy; J E Street; E R Mackow; L Fiore; L Rott; H B Greenberg
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Authors:  J Jameson; J Cruz; F A Ennis
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype N1.

Authors:  M Wysocka; C J Hackett
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 8.  T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine.

Authors:  Anna Schmidt; Dennis Lapuente
Journal:  Viruses       Date:  2021-01-28       Impact factor: 5.048

9.  Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.

Authors:  Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2020-03-13       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.